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July 1, 2008:82–4esults confirm previously published forensic evidence demonstrat-
ng that EVs could be significantly associated with sudden cardiac
nexpected death cases (2). Evidently, it has been previously
stablished that these EV cardiotropic strains did not respect
ational borders (2–5).
In this study (1), the endomyocardial detection of viral capsid
rotein 1 (VP1) by immunohistochemical technique was found to
e the best tool for the diagnosis of EV-associated heart diseases as
reviously described (4,5), and no heart tissue control samples were
P1 positive using our improved immunohistological protocols
6). The VP1 results were confirmed by molecular assays and in
ome cases by the use, after cloning, of nucleic acid sequencing of
he VP1 region (1). Moreover, none of the 20 EV-positive patients
ith acute MI and none of the 2 EV-positive subjects from the
ealthy heart control group were positive for the detection of other
ardiotropic viruses, including Epstein-Barr virus, herpes simplex
iruses, cytomegalovirus, varicella-zoster virus, adenoviruses, and
arvovirus B19, in their myocardial tissues using previously pub-
ished polymerase chain reaction techniques (1). However, 60% of
he EV-negative heart tissues of MI patients were positive for the
olecular detection of 1 or several of these cardiotropic viruses,
ncluding parvovirus B19 (not shown). These results support the
revious published data on the potential role of myocardial virus
ersistence in differential aspects of endothelial function of the
oronary microcirculation endothelial activation, and myocardial
eukocyte infiltrates (7–9). By consequence, the role of other
ardiotropic viruses including parvovirus B19-persistent infection
n the development of coronary diseases remains to be explored,
nd it, therefore, is possible that other viruses may be associated to
V cardiovascular infections and may trigger the inflammatory
rocess of chronic arteriosclerosis leading to acute MI (7).
Finally, there is no evidence of a new element of the “French
aradox” related to the way of life including wine drinking, and
hich may concern a specific cardiovascular protection against
ommon cardiotropic viruses (8). However, the French red wine is
etter than German beer for our arteries, but this drink remains to
e consumed with moderation (10).
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he Challenges of Cardiovascular
esearch in Developing Countries
e read with interest the recent article by Prabhakaran et al. (1)
eporting the results of the Global Cardiovascular Disease Re-
earch Survey. Not surprisingly, the study shows a low research
utput in developing (low-income and low-middle-income) coun-
ries. The authors postulate that a major reason for this low output
s low government spending, and they recommend that govern-
ents in these countries increase their research funding to improve
esearch output.
The issues related to research and funding in developing
ountries are complicated and multifactorial. It is easy to say that
ncreasing research funding in these countries will improve their
roductivity, and this is probably true. Yet, the implementation of
his recommendation is difficult. It is very difficult to convince
overnments in developing countries, with limited financial re-
ources, to invest in research when a significant percentage of their
opulations still does not have water and electricity supplies.
imilarly, it is very difficult for universities and hospitals to invest
n research when their financial resources can barely fulfill their
asic requirements in medical care and medical education.
Furthermore, although funding is certainly an essential compo-
ent in the advancement of research, it is not the only one.
nother very important component, which is not easy to study and
nalyze, is human resources. Performing high-quality research
equires the recruitment of established senior investigators who can
nhance research productivity and, more importantly, train young
unior investigators to sustain research activity. These high-quality
nvestigators require not only funding but also political, economic,
nd social stability. The U.S. and Europe have thousands of
nvestigators who originally came from developing countries.
hese scientists reside in the U.S. and Europe not only because of
he availability of funds but also because of political, economic, and
ocial stability that they do not have in their home countries.
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July 1, 2008:82–4With all of these limitations, does this mean that developing
ountries should forget about medical research? No, but they
hould have realistic expectations and rational policies that can
uide the utilization of their very limited resources. These policies
hould probably focus research funding on selective centers with
elected high-quality investigators who can use these resources to
roduce high-quality research. It is also very important to encour-
ge collaboration with investigators and institutions in developed
ountries. We have recently analyzed the research productivity of
he medical faculty in our institution (2) and found that collabo-
ation with investigators in developed countries significantly im-
roved the quality of our medical center’s research output.
Cardiovascular research is essential for the advancement of
uman health. The study by Prabhakaran et al. (1) indicates that
eveloping countries have not yet made significant contributions in
his field, in spite of the fact that their populations carry a major
ercentage of the global burden of cardiovascular diseases. The
roblem is clear. The solutions, however, are very difficult.
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eply
e thank Dr. Dakik for his interest in and comments on our
rticle (1). We largely agree with his observations about the
ultifactorial determinants of the low research output related to
ardiovascular disease (CVD) research in low-income and low-
iddle-income countries. We do, however, differ with some
erspectives. For example, Dr. Dakik argues that collaboration
ith investigators in developed countries raises the quality of
ublished articles. Although this is true to some extent, it hampers
ocal capacity enhancement and original research from developing-
ountry scientists, as in most such publications, the corresponding
uthors are from the developed country (data not shown). Further,here are hardly any collaborative studies aimed at improving
ealth systems, quality of care, and translational research. Collab-
ration with developed-country investigators, in the absence of
ational funding, compels developing-country investigators to
ccept research agendas set by their funding partners. Availability
f national funding for research enables a greater balance to be
ttained in research undertaken by developing-country investiga-
ors. The aim of our article was to raise awareness of the low
riority afforded to CVD and to argue for enhanced allocation of
esources to CVD prevention and control.
In addition, there is a lack of information on how the estimated
2.4 billion spent by low- and middle-income countries in health
esearch and development in 2003 (2) was allocated across different
isease or disciplinary categories. Although anecdotal information
rom these countries suggests that public-sector spending on CVD-
elated research is limited, this question needs further systematic
uantification.
Although we need to further study the issues raised by Dr.
akik, as well as other determinants of the volume and variety of
VD-related research, we cannot ignore the advancing epidemic
f CVD in developing countries. Therefore, governments need to
pend at least a small portion of their funds on translational and
perational research for enhancing the provision of inexpensive,
ffective, and evidence-based care for established CVD and to
evelop cost-effective strategies aimed at health promotion for
rimary prevention of CVD.
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